Shares in Swedish microcap Nanexa more than doubled at the open in Stockholm on Friday after the drug-delivery group disclosed a global licensing agreement with Novo Nordisk valued at up to $1.33 billion. The stock pared gains to around 114 percent by late morning, leaving it roughly 12 percent below its November 2015 all-time high.
The deal structure
Novo Nordisk, the maker of Wegovy and Ozempic, secures exclusive rights to use Nanexa's PharmaShell technology across up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. PharmaShell applies an ultra-thin inorganic coating to drug particles to control their release over time, with the partners aiming for monthly and quarterly dosing schedules. Nanexa is eligible for an upfront payment of around $700 million plus milestone payments tied to development and regulatory progress, and low single-digit royalties on any resulting product sales.
Revenue context
The agreement dwarfs Nanexa's existing business. The company reported full-year 2025 revenue of approximately $3.89 million, a 48.4 percent increase on the prior year. The upfront portion alone represents roughly 180 times that annual figure. "With this agreement, Nanexa enters a new era of considerable financial strength, allowing us to significantly expand applications of our unique [atomic layer deposition] technology to other therapeutic areas and giving us an opportunity to build a sustainable long-term business," said chair Göran Ando.
What the market is pricing
Chief executive David Westburg said the deal "provides a strong foundation for expanding PharmaShell into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept, allowing us to capture greater value from the breadth of the PharmaShell platform." The share move suggests investors are valuing the optionality of the platform well beyond the near-term milestones, even though the royalty rate remains in the low single digits and the five programs have yet to enter development.
What to watch
The critical test will be whether PharmaShell can translate Novo's GLP-1 franchise from weekly to monthly or quarterly dosing without compromising efficacy or safety. Clinical timelines, milestone triggers and any disclosure of which specific molecules are in the first wave of programs will determine how much of the $1.33 billion headline value ever materializes. For now, a company that traded as a microcap on the Nasdaq First North Growth Market has a partnership that exceeds its market capitalization by an order of magnitude.